SERBIA

VHPB BALKAN MEETING **CURRENT SITUATION:** EPIDEMIOLOGY, BURDEN OF **DISEASE, SCREENING &** PREVENTION, CASCADE OF CARF





The prevalence of HCV infection in Serbia is estimated ~ $1.13\%^*$

COUNTRY EPIDEMIOLOGY

	HBsAg (2020)	Anti-HCV (2020)
General population	0,7% (76/192145)	0,5% (1461286260)
Blood donors (first time)	0,8% (76/192145)	0,03% (49/192145)
Pregnant women	0,4% (56/29117)	0,2% (22/11517)
Risk Groups PWID MSM Prisoners Other Healthcare workers	1,5% (6/819) 3,2% (4/251) 0 0,3%(19/11089) 0,5% (2/765)	11,9% (111/937) 15 (3/300) 0 1,4% (108/7630) 0,3% (2/669)



COUNTRY VACCINATION PROGRAM

Hepatitis A	Y/N	population + Schedule	Since/period
Universal	Ν		
Risk group	Y		

Hepatitis B	Y/N	population + Schedule	Since/period
Universal	Y	birth	2002
Catch-up	Y		
Risk Group	Y		



Active immunization against hepatitis B is carried out pre-exposure in:

- I. sexual partners of HBsAg positive persons,
- 2. residents of institutions for the developmentally disabled,
- 3. intravenous drug addicts,
- 4. persons in institutions for the execution of criminal sanctions,
- 5. household contacts of HbsAg positive persons.
- Active and passive immunization against hepatitis **B** is carried out post-exposure code:
- I. newborns of HBsAg positive mothers,
- 2. persons who had an accident with infectious material,
- 3. pregnant women with liver damage, if they were exposed to infection.



- Active immunization against hepatitis B is carried out in:
- I. suffering from hemophilia and other diseases that require the use of blood derivatives,
- 2. person on hemodialysis,
- 3. insulin dependent patients from diabetes,
- 4. liver transplantation.
- Passenger immunization program

COUNTRY SCREENING

Recommended for following groups:	Нер В	Нер С
General population	Ν	N
Birth cohorts	Ν	Ν
Blood and organ donors	Y	Y
Pregnant women	Y	Y
PWID	Y	Y
STI clinic patients	Y	Y
Haemodialysis patients	Y	Y
Health care workers	Y	Y
Men having sex with men	Y	Y
Prison population	Y/N	Y/N
Migrants	Y/N	Y/N
Others		



COUNTRY TREATMENT

National guidelines available	Y/N (year)
Hepatitis B	Ν
Hepatitis C	Ν
Other (specify)	



COUNTRY TREATMENT

Drugs available for HCV treatment*	Y/N
PegInterferon	Ν
Ribavirin	Y
Boceprevir	Ν
Telaprevir	Ν
Simeprevir	Ν
Sofosbuvir	Ν
Daclatasvir	Ν
Sofosbuvir/Ledipasvir	Y
Sofosbuvir/Velpatasvir	Y
Glecaprevir/Pibrentasvir	Y
Sofosbuvir/Velpatasvir/Voxilaprevir	Ν
Elbasvir/Grazoprevir	Y


Drugs available for HBV treatment*	Y/N
Lamivudine	Y
Adefovir	Ν
Telbivudine	Ν
Entacavir	Ν
TDF	Y
TAF	Y

Number of patients treated (cumulative)		
Нер В	2000	
Нер С	5500	

*included on the national essential medicines list or subsidized by the government



VIRAL HEPATITIS BAND C





Treatment of HCV infection in Serbia has been accompanied by numerous problems.

HCVTREATMENT IN SERBIA

- modern DAA was introduced in 2018
- very rigorous criteria
- exclusively for patients with cirrhosis
- 60 patients a year (218 patients from 2018-2020)